Assessing the quality of bowel preparation by addition of Movicol to standard bowel preparation regimen in patients undergoing routine colonoscopy: a randomized controlled trial

Alfred Health0 个研究点目标入组 362 人开始时间: 2016年5月30日最近更新: 2020年1月13日

试验速览

暂无简介。

•Consenting adult patients referred for outpatient colonoscopy procedure for clinically accepted indications (these generally include but are not restricted to iron deficiency anaemia, surveillance of bowel polyps, colorectal cancer screening, assessment of symptoms such as abdominal pain, diarrhoea and constipation, assessment or investigation of inflammatory bowel disease)

•Exclusion criteria are as follows:
•Conditions which are exclusions to colonoscopy in normal clinical practice (suspected bowel perforation, gastric outlet obstruction, toxic megacolon, severer colitis, pregnancy or lactation)
•Significant renal failure (eGFR<30)
•Significant heart failure (New York Heart Association Class III or IV)
•Type 1 diabetes
•Cystic fibrosis
•Phenylketonuria (Prepkit C contraindicated)
•Known hypersensitivity to a constituent of Picoprep, Glycoprep or Picosalax and Movicol
•(Type 1 diabetics or Cystic Fibrosis patients are excluded as they follow specific guidelines for bowel preparation for colonoscopy at Alfred Hospital.)

发起方